FindTrial
Sign In

Hexagene methylation detection: A new strategy for early screening and prevention of cervical cancer

Research on the Application of Host six-Gene Methylation Detection in the Prevention and Treatment of Cervical Cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600123569
Enrollment
Unknown
Registered
2026-04-28
Start date
2025-05-30
Completion date
Unknown
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical cancer

Interventions

Patients who are scheduled to undergo cervical exfoliation cytology examination:none

Sponsors

The First Affiliated Hospital of Fujian Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Female patients who underwent cervical cytology examination in our hospital. 2.Those with complete clinical data and follow-up information;

Exclusion criteria

Exclusion criteria: 1. Exclude metastatic cancer of the cervix. 2.Exclude those with a history of other malignant tumors. 3. Exclude those who have received preoperative radiotherapy, chemotherapy or hormone therapy;

Design outcomes

Primary

MeasureTime frame
Cervical cancer risk screening results;Sensitivity; specificity;—

Countries

China

Contacts

Public ContactYuhong Ye

The First Affiliated Hospital of Fujian Medical University

yeyuhong519@163.com+86 591 8798 1654

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 7, 2026